WO2020081072A1 - Intraocular lenses with embedded intraocular pressure sensors - Google Patents

Intraocular lenses with embedded intraocular pressure sensors Download PDF

Info

Publication number
WO2020081072A1
WO2020081072A1 PCT/US2018/056277 US2018056277W WO2020081072A1 WO 2020081072 A1 WO2020081072 A1 WO 2020081072A1 US 2018056277 W US2018056277 W US 2018056277W WO 2020081072 A1 WO2020081072 A1 WO 2020081072A1
Authority
WO
WIPO (PCT)
Prior art keywords
iol
sensor
optic
iop
intraocular
Prior art date
Application number
PCT/US2018/056277
Other languages
French (fr)
Inventor
Douglas P. ADAMS
Amitava Gupta
Jean-Noel Fehr
Alain SAUER
Original Assignee
Qura, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qura, Inc. filed Critical Qura, Inc.
Priority to PCT/US2018/056277 priority Critical patent/WO2020081072A1/en
Publication of WO2020081072A1 publication Critical patent/WO2020081072A1/en
Priority to US17/066,564 priority patent/US20210137379A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/16Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for measuring intraocular pressure, e.g. tonometers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/14Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • A61F2/16Intraocular lenses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/14Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • A61F2/16Intraocular lenses
    • A61F2002/1681Intraocular lenses having supporting structure for lens, e.g. haptics
    • A61F2002/1689Intraocular lenses having supporting structure for lens, e.g. haptics having plate-haptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0001Means for transferring electromagnetic energy to implants
    • A61F2250/0002Means for transferring electromagnetic energy to implants for data transfer

Definitions

  • Intraocular lenses are typically permanent, plastic lenses that are surgically implanted inside of the eyeball to replace or supplement the eye's natural crystalline lens. They have been used in the United States since the late l960s to restore vision to cataract patients, and more recently are being used in several types of refractive eye surgery.
  • the natural crystalline lens is a critical component of the complex optical system of the eye.
  • the crystalline lens provides about 17 diopters of the total 60 diopters of the refractive power of a healthy human eye.
  • Most intraocular lenses used in cataract surgery may be folded and inserted through the same tiny opening that was used to remove the natural crystalline lens. Once in the eye, the lens may unfold to its full size.
  • the opening in the eye may be as small as 2.5 mm in length, so that it heals itself quickly without stitches.
  • the intraocular lenses may be made of inert materials or they may have a biocompatible coating that does not trigger rejection responses by the body.
  • IOLs are permanent. They rarely need replacement, except in the instances where the measurements of the eye prior to surgery have not accurately determined the required focusing power of the IOL. Also, the surgery itself may change the optical characteristics of the eye. In most cases, the intraocular lenses implanted during cataract surgery are monofocal lenses, and the optical power of the IOL is selected such that the power of the eye is set for distance vision. Therefore, in most cases the patient will still require reading glasses after surgery lntraocular lens implants may be static multifocal lenses, which attempt to function more like the eye's natural lens by providing clear vision at a distance and reasonable focus for a range of near distances, for patients with presbyopia.
  • IOLs have been implanted in canines, mainly household pet dogs, after cataract extraction.
  • Commonly affected breeds include the American cocker spaniel, poodle, Boston terrier, miniature Schnauzer, Bichon Frise, and Labrador retriever.
  • genetic lenticular opacities are bilateral and slowly progressive. Rapidly progressive cataracts commonly occur in dogs with diabetes mellitus.
  • Secondary lens-induced uveitis is a frequent finding that may complicate pre- and postoperative management (Cook, C,“Canine Cataract Surgery”, in Cataract & Refractive Surgery Today, 2008; pp 32).
  • An exemplary intraocular lens 2 developed for implantation in canines is shown in figure 1.
  • Figure 1 which is a hydrophilic posterior chamber intraocular implant (PCL) developed for canines (Manufactured by Bausch and Lomb). The dimensions of this intraocular lens and its intended site of implantation are given in Table 1.
  • PCL hydrophilic posterior chamber intraocular implant
  • Table 1 Dimensions and other specifications of a posterior chamber intraoocular lens (PCL) designed for canines.
  • PCL posterior chamber intraoocular lens
  • Glaucoma has been diagnosed in nearly 15% of the population in USA above age 80. The incidence of glaucoma rises with age, and is more prevalent in the African American and Hispanic population segment in USA. Many of these patients develop cataract at an earlier age (typically between 50 and 75 years of age), and undergo cataract extraction and in virtually all cases implantation of an intraocular lens. Many of these pseudophakes or aphakes, especially those with diabetes may develop glaucoma, including angle closure glaucoma caused by post operative inflammation.
  • Postoperative increase in intraocular pressure may be caused by residual viscoelastic gels left over after surgery, incursion of the vitreous caused by breach of the posterior capsule during cataract surgery, or iatrogenic damage to the iris, leading to pigment dispersion or the Ugh (uveitis-glaucoma-hyphema) syndrome.
  • Ugh uveitis-glaucoma-hyphema
  • Occurrence of glaucoma after cataract surgery is especially prevalent in canines, partly because canines tend to experience a substantially higher level of postoperative inflammation subsequent to cataract surgery.
  • Biros, et al reported a study of 346 canine eyes, in which they monitored incidence of glaucoma as a function of eight variables, including breed, sex, post-operative hypertension, and intraocular lens placement. Of the 346 eyes, 58 (16.8%) developed glaucoma after surgery. At 6 months, 32 of 206 (15.5%) eyes examined had glaucoma; at 12 months, 44 of 153 (28.8%) eyes examined had glaucoma. Median follow-up time was 5.8 months (range, 0.1 to 48 months). Mixed-breed dogs were at a significantly lower risk for glaucoma, compared with other breeds.
  • Eyes without IOL placement were at a significantly lower risk for glaucoma, compared with eyes with IOL placement. Eyes with hypermature cataracts were at a significantly higher risk for glaucoma, compared with eyes with mature or immature cataracts (Biros, et al,“Development of glaucoma after cataract surgery in dogs”, in J Am Vet Med Assoc., 2000; 216(11), pp 1780).
  • an intraocular lens comprising: an optic and a plate haptic configured for four point fixation in the eye, optionally within a capsular sac; and an embedded intraocular pressure (“IOP”) sensor assembly, wherein the intraocular pressure sensor assembly is mounted on a transparent substrate, wherein the substrate is attached to an anterior surface of the intraocular lens, and wherein the optic is wholly or substantially free from obscuration.
  • IOP embedded intraocular pressure
  • One aspect of the disclosure is a method of manufacturing an IOL, comprising: providing an IOL that includes an optic and a plate haptic; positioning an intraocular pressure sensor above an anterior side of the plate haptic; optionally positioning a soft gel above the IOL sensor;
  • One aspect of the disclosure is a method of folding an IOL for delivery, comprising: providing an IOL that includes an optic and a plate haptic, and a pressure sensor disposed on the plate haptic; and folding the IOL along at least one fold line that is on a first side of the pressure sensor, the fold line not passing through an optical axis of the optic.
  • One aspect of the disclosure is an intraocular lens, comprising: an optic and at least one plate haptic, and a pressure sensor embedded in the plate haptic.
  • One aspect of the disclosure is an intraocular lens, comprising: an optic and at least one plate haptic; and an antenna extending around a periphery of the IOL.
  • Figure 1 illustrates an exemplary intraocular lens developed for implantation in canines.
  • Figure 2 illustrates an earlier exemplary IOL with an attached sensor.
  • Figures 3A and 3B illustrate an earlier exemplary IOL with an attached sensor.
  • Figure 4 illustrates an exemplary rigid PCB.
  • Figure 5 illustrates an exemplary flexible and transparent PCB.
  • Figure 6 illustrates details of an exemplary microstructure and layering of a multi-layer film.
  • Figures 7A, 7B and 7C illustrate an exemplary plate haptic IOL with an embedded intraocular pressure assembly.
  • Figure 8 illustrates an exemplary layering of components for any of the IOLs herein.
  • the present disclosure is related to the field of IOLs.
  • the present disclosure relates to IOL wherein one or more sensors is attached (directly or indirectly) to at least one of the optic and the haptic(s) surface of the IOL, ensuring that the sensor does not significantly affect the optical performance or stability of the IOL in the eye.
  • the sensor is an intraocular pressure sensor.
  • an intraocular sensor module means a capacitative or piezoresistive sensor that may comprise a separate package, or be on die (fabricated on the same silicon substrate as the rest of the electronic components).
  • An intraocular pressure sensor assembly means the intraocular sensor and all the electronics that are may be used to operate the sensor, including, without limitation a microcontroller, voltage amplifiers, resistors and capacitors, memory units, RFID modules, batteries, and so on.
  • the intraocular pressure sensor can be mounted (directly or indirectly) on an intraocular lens, preferably designed for implantation in the posterior chamber. Attachment of an intraocular pressure sensor to the body an IOL has several advantages relative to commonly prescribed sites of fixation of such a sensor in intraocular space, for example, in the sclera (making it an intrascleral implant), in the subconjunctival space, the superchoroidal region, the vitreous, or in or near the Schlemms canal.
  • An exemplary advantage of a sensor embedded in an IOL is that, by being embedded in the body of an IOL, the sensor is safely away from ocular tissue that may be otherwise disrupted by touch of the sensor body, for example, the iris or the corneal endothelium.
  • the senor is embedded on the anterior side of the IOL body and the IOL is placed in the capsular sac, the sensor is covered by the anterior capsule, and provided another layer of isolation and protected from cellular deposits and growth. At the same time, it is surrounded by flowing aqueous humor so that the pressure recorded by the sensor is the true intraocular pressure. Sensors embedded in the sclera, the vitreous or the subconjunctival space do not record pressure of the free flowing aqueous humor, but of ocular tissue in mechanical contact with the aqueous humor. The sensed pressure for those devices is therefore dampened by the modulus and the viscoelastic properties of the ocular tissue that surrounds the sensor.
  • Figure 2 shows an exemplary intraocular lens 4 with an intraocular pressure sensor 10 mounted on its surface.
  • Antenna 6 can be made of copper or a gold-titanium alloy, coated with gold, and is mounted around the periphery of the optic, as shown.
  • the IOL also includes electronics 8 in communication with at least one of the antenna 6 and the pressure sensor 10.
  • Pressure sensor 10 extends into the optical zone of the optic, and the antenna extends around the periphery of the optic portion.
  • Figures 3A and 3B show an exemplary intraocular pressure sensor assembly 14 positioned on the anterior surface of an exemplary canine posterior chamber IOL 12.
  • Antenna 16 is also shown extending around the periphery of the optic portion of the IOL. Again, the pressure sensor assembly 14 extends into a portion of the optic zone of the optic. Exemplary non-limiting dimensions include an optic diameter of 6 mm and overall length of the IOL of 14 mm.
  • Transparent PCBs are a recent development, and the initial development led to rigid, transparent PCBs, as example of which is shown in Figure 4.
  • the exemplary transparent PCB of figure 4 can be made of
  • Exemplary advantages of transparent Alumina PCB include transparency up to 80-90%; high operating temperature up to 350°C; low expansion coefficient strong thermal properties (e.g., 26-28 W/mK); multi-layer circuits are possible; hermetic packages possible; and 0% water absorption.
  • Other types of transparent PCBs have also been commercialized, utilizing polyimide, polyethylene
  • the film is a multilayer structure 20 (see figure 6), comprised of a polymer film 24 with barrier properties such as Paralyne -C interspersed with layers of ceramic 22 such as SiOx.
  • the ceramic material is the relatively thinner horizontal layers, and the polymeric material is represented as the relatively thicker horizontal layers.
  • the film can be formed either as a free standing film, or a conformal coating to provide a hermetic seal around an implant or a portion of an implant, as disclosed in the following patents, incorporated by reference herein for all purposes, including methods of manufacture and methods of application to other materials - US Pat. No. 8,313,811; US Pat. No. 8,313,819; and US Pat. No. 8,361,591. Any and all methods of manufacturing and deposition described in these references are fully incorporated herein and can be used to manufacture any of the flexible components onto the IOLs herein.
  • Figure 6 shows details of exemplary microstructure and layering of these multi-layer films, illustrating permeation and diffusion by the arrows.
  • the structure of the film can be used to alter or control the permeation and diffusion. Their effect on permeation and diffusion properties of these films have been discussed by Dr. Andreas Hogg in his Ph.D. thesis.
  • FIGS 7A, 7B and 7C are top, side, and front views of an exemplary plate haptic IOL with an embedded intraocular pressure assembly.
  • the IOL in figures 7A, 7B and 7C is a plate haptic IOL that is adapted to be foldable, and exemplary folding lines are shown as the two dashed lines.
  • Figs. 7A-7C illustrate exemplary IOL 40, which includes optic portion 42 and plate haptic portion 44.
  • IOL also includes an intraocular pressure sensor assembly that includes sensor module 46 and electronics module 48, which are in electrical communication via electrical connectors 52.
  • the IOL also includes antenna 50, which extends around the periphery of the IOL as shown, and is in electrical communication with connectors 52.
  • Exemplary dimensions between the folding lines and sensor module 6 are .1 mm to .6 mm, such as .2mm to .45 mm, such as .35 mm.
  • sensor module 46 and electronics module 46 are embedded in the plate haptics of the IOL.
  • the multilayer barrier film has been utilized to populate the electronic module, for example, comprising a microcontroller, an intraocular pressure sensor, a memory, and an RFID module on the haptic of the plate haptic IOL.
  • the location of the printed circuitry shown in figure 7 is an example and is not intended to be limiting.
  • the antenna 50 and the conductive bus 52 may be disposed along the periphery of the IOL body, enabling the deployment of a substantially longer antenna loop, relative to the earlier designs shown in Figures 2 and 3.
  • the overall length of the loop antenna can be in the range of 20.0 mm - 30.0 mm, preferably in the range 22.0 mm to 26.0 mm.
  • the antenna can be made of a wire of, for example, a diameter of 100 microns (such as in a range of 25-200 microns), and is preferably mounted on the anterior surface of the intraocular lens.
  • the antenna can be comprised of a thin plate of gold or Nitinol coated with Gold, of thickness in the range of 10-50 microns and width in the range of 100 - 250 microns.
  • the advantage of utilizing Nitinol in the antenna is that use of Nitinol improves the unfolding characteristics of the haptic subsequent to implantation through a small incision.
  • the antenna and all other electrical elements may be bonded to the transparent multilayer film that is bonded to the surface of the intraocular lens, preferably the anterior surface.
  • the antenna and the conductive bus may be directly deposited (e.g., via physical or chemical vapor deposition) on the transparent multilayer film.
  • the overall thickness of the multilayer film can be about 10-100 microns (preferably, 20-75 microns).
  • the implant comprising the IOL and the embedded intraocular pressure sensor, coated with the multilayer coating disclosed by Hogg is preferably coated with an organic
  • the coating can be a multilayer amphiphilic or hydrophilic coating, with a gradation of cross-link density, glass transition temperature and bulk modulus. Its microstructure is that of a scaffold, with an inner layer with the highest cross-link density, and an outer layer of lowest cross-link density.
  • the coating is applied via photopolymerization and comprises polyethylene glycol segments terminated with acrylate or methacrylate groups.
  • the plate haptic IOLs disclosed herein can be configured to engage the capsular equator at four points, and is therefore quite resistant to rotational displacement. It may not be vaulted, but a vault of up to 7 degrees is acceptable. A vault further separates the intraocular sensor assembly from the iris.
  • the overall length of the IOL can be between 11.5 and 12.7 mm, preferably 12.5 mm. In exemplary figure 7A the exemplary length is shown as 12.3 mm.
  • the IOL is preferably implanted in a folded state, preferably along lines bordering (on at least one side of) the electronic modules and the sensor module, such as is shown in figure 7 A.
  • Such a folding pattern will enable the IOL to be delivered through a 3.3 mm incision.
  • the haptic portions of the IOL can also be adapted to be more preferential to folding along the folding lines to facilitate folding in particular areas on both sides of the electronics modules and the sensor module.
  • IOL designs herein provides a full diameter optic, 6.0 mm in diameter.
  • Alternative designs may be provided that have an optic of diameter from 5.0 mm to 6.5 mm, with an outer diameter of 6.0 to 7.5 mm.
  • a second major advantage is that the IOLs herein allow an antenna of total length in the range of 20.0 to 25.0 mm, more than three time the length provided by previous designs.
  • the edge of the preferred plate haptic IOL is preferably designed to have a square profile. Since the edge of the optic has a thickness in the range of 50-150 microns, the overall thickness of the edge bearing the antenna coil will be in the range 150 - 525 microns, preferably 200-400 microns. This increase in edge thickness and a barrier on the anterior surface may eliminate migration of residual cortical and equatorial cells left over after phacoemulsification and cleaning of the capsular sac prior to lens implantation to the posterior capsule, and thus helps inhibit posterior capsular opacification (“PCO”).
  • PCO posterior capsular opacification
  • biocompatible coatings have been disclosed previously.
  • it is made of a hydrogel material, and comprises two or more layers.
  • the inner layers of this coating is preferably infused with pharmaceuticals, including an anticlotting agent, an antifibrotic agent, a corticosteroid and some other medicaments that downregulate expression of inflammation mediators such as cytokines.
  • the multilayer coating similar in molecular structure to an extracellular matrix prevents adhesion of giant cells, or polymorphic macrophage.
  • Figure 8 illustrates an exemplary layering of components for any of the IOLs herein.
  • the sensor can be disposed above an anterior side of an IOL.
  • An optional gel can be applied above the sensor or other sensor components.
  • the multilayer barrier coating can then be positioned, which can be covered by an optional biocompatible coating.
  • substantially free can mean that not less than 90% of the surface area is free of obscuration, or not less than 95%, or not less than 96%, or not less than 97%, or not less than 98%, or not less than 99%.
  • antenna 50 may extend slightly over the optic zone of the optic, but insignificantly.

Abstract

Intraocular lenses with embedded pressure sensor assemblies. The intraocular lenses can include a multilayer barrier coating disposed over at least a portion of the IOL. The intraocular lenses can also include an antenna extending along a periphery of the IOL.

Description

INTRAOCULAR LENSES WITH EMBEDDED INTRAOCULAR
PRESSURE SENSORS
INCORPORATION BY REFERENCE
[0001] All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
BACKGROUND
[0002] Intraocular lenses (“IOLs”) are typically permanent, plastic lenses that are surgically implanted inside of the eyeball to replace or supplement the eye's natural crystalline lens. They have been used in the United States since the late l960s to restore vision to cataract patients, and more recently are being used in several types of refractive eye surgery.
[0003] The natural crystalline lens is a critical component of the complex optical system of the eye. The crystalline lens provides about 17 diopters of the total 60 diopters of the refractive power of a healthy human eye. Most intraocular lenses used in cataract surgery may be folded and inserted through the same tiny opening that was used to remove the natural crystalline lens. Once in the eye, the lens may unfold to its full size. The opening in the eye may be as small as 2.5 mm in length, so that it heals itself quickly without stitches. The intraocular lenses may be made of inert materials or they may have a biocompatible coating that does not trigger rejection responses by the body.
[0004] In most cases, IOLs are permanent. They rarely need replacement, except in the instances where the measurements of the eye prior to surgery have not accurately determined the required focusing power of the IOL. Also, the surgery itself may change the optical characteristics of the eye. In most cases, the intraocular lenses implanted during cataract surgery are monofocal lenses, and the optical power of the IOL is selected such that the power of the eye is set for distance vision. Therefore, in most cases the patient will still require reading glasses after surgery lntraocular lens implants may be static multifocal lenses, which attempt to function more like the eye's natural lens by providing clear vision at a distance and reasonable focus for a range of near distances, for patients with presbyopia.
[0005] Recently, IOLs have been implanted in canines, mainly household pet dogs, after cataract extraction. Commonly affected breeds include the American cocker spaniel, poodle, Boston terrier, miniature Schnauzer, Bichon Frise, and Labrador retriever. Typically, genetic lenticular opacities are bilateral and slowly progressive. Rapidly progressive cataracts commonly occur in dogs with diabetes mellitus. Secondary lens-induced uveitis is a frequent finding that may complicate pre- and postoperative management (Cook, C,“Canine Cataract Surgery”, in Cataract & Refractive Surgery Today, 2008; pp 32). An exemplary intraocular lens 2 developed for implantation in canines is shown in figure 1. Figure 1, which is a hydrophilic posterior chamber intraocular implant (PCL) developed for canines (Manufactured by Bausch and Lomb). The dimensions of this intraocular lens and its intended site of implantation are given in Table 1.
[0006] Table 1. Dimensions and other specifications of a posterior chamber intraoocular lens (PCL) designed for canines.
Figure imgf000003_0001
[0007] A considerable number of patients needing to undergo cataract surgery have preexisting glaucoma. Glaucoma has been diagnosed in nearly 15% of the population in USA above age 80. The incidence of glaucoma rises with age, and is more prevalent in the African American and Hispanic population segment in USA. Many of these patients develop cataract at an earlier age (typically between 50 and 75 years of age), and undergo cataract extraction and in virtually all cases implantation of an intraocular lens. Many of these pseudophakes or aphakes, especially those with diabetes may develop glaucoma, including angle closure glaucoma caused by post operative inflammation.
[0008] Postoperative increase in intraocular pressure may be caused by residual viscoelastic gels left over after surgery, incursion of the vitreous caused by breach of the posterior capsule during cataract surgery, or iatrogenic damage to the iris, leading to pigment dispersion or the Ugh (uveitis-glaucoma-hyphema) syndrome. Moreover a certain percentage of persons who develop glaucoma at a relatively early age subsequently develop cataract and undergo cataract extraction and implantation of an intraocular lens.
[0009] Models based on UN world population projections predict that in the year 2020, 79.6 million persons will be afflicted with either open-angle glaucoma (OAG) or angle-closure glaucoma (ACG) with 5.9 million and 5.3 million projected to be bilaterally blind from these two conditions, respectively. (Kung, JS, et al,“Cataract surgery in glaucoma patient” in Middle east Afr J Ophthalmol, 2015; 22(1), pp 10-17.).
[0010] Occurrence of glaucoma after cataract surgery is especially prevalent in canines, partly because canines tend to experience a substantially higher level of postoperative inflammation subsequent to cataract surgery.
[0011] The prevalence of the primary breed-related glaucomas has gradually increased from 0.29% (1964-1973); 0.46% (1974-1983); 0.76% (1984-1993); to 0.89% (1994-2002). Breeds that consistently featured among the highest 10 for glaucoma prevalence from four different periods (1964 to 2002) included American Cocker Spaniel, Basset Hound, Wire Fox Terrier, and Boston Terrier. During the last observation period (1994-2002), 22 different breeds had 1% or higher prevalence of the glaucomas. The highest prevalence of glaucomas in 1994-2002 by breed included: American Cocker Spaniel (5.52%); Basset Hound (5.44%); Chow Chow
(4.70%); Shar-Pei (4.40%); Boston Terrier (2.88%); Wire Fox Terrier (2.28%); Norwegian ElkHound (1.98%); Siberian Husky (1.88%); Cairn Terrier (1.82%); and Miniature Poodle (1.68%). A predominance of females with glaucoma occurred in the American Cocker Spaniel, Basset Hound, Caim Terrier, Chow Chow, English Cocker Spaniel, Samoyed, and perhaps the Siberian Husky, and a predominance of males in the Australian Cattle dog and St Bernard. Age affected the time for first presentation of the glaucoma in the pure-bred dog. In the majority of breeds the glaucoma was presented for initial diagnosis in dogs between 4 and 10 years of age (Gellat KN, and McKay, EO,“Prevalence of the breed related glaucoma in pure bred dogs in North America”, in Vet Ophthalmol, 2004; 7(2), pp 97).
[0012] Biros, et al, reported a study of 346 canine eyes, in which they monitored incidence of glaucoma as a function of eight variables, including breed, sex, post-operative hypertension, and intraocular lens placement. Of the 346 eyes, 58 (16.8%) developed glaucoma after surgery. At 6 months, 32 of 206 (15.5%) eyes examined had glaucoma; at 12 months, 44 of 153 (28.8%) eyes examined had glaucoma. Median follow-up time was 5.8 months (range, 0.1 to 48 months). Mixed-breed dogs were at a significantly lower risk for glaucoma, compared with other breeds. Eyes without IOL placement were at a significantly lower risk for glaucoma, compared with eyes with IOL placement. Eyes with hypermature cataracts were at a significantly higher risk for glaucoma, compared with eyes with mature or immature cataracts (Biros, et al,“Development of glaucoma after cataract surgery in dogs”, in J Am Vet Med Assoc., 2000; 216(11), pp 1780).
[0013] Therefore, regular and frequent monitoring of intraocular pressure is critically important during the immediate post-operative period following cataract surgery. In the long run, regular monitoring of intraocular pressure is required to track continued efficacy of pressure controlling medications and monitor compliance. Both of these needs require introduction of an implanted, intraocular pressure sensor that can wirelessly transmit data to an external unit without any involvement of the patient.
SUMMARY OF THE DISCLOSURE
[0014] One aspect of the disclosure is an intraocular lens, comprising: an optic and a plate haptic configured for four point fixation in the eye, optionally within a capsular sac; and an embedded intraocular pressure (“IOP”) sensor assembly, wherein the intraocular pressure sensor assembly is mounted on a transparent substrate, wherein the substrate is attached to an anterior surface of the intraocular lens, and wherein the optic is wholly or substantially free from obscuration.
[0015] One aspect of the disclosure is a method of manufacturing an IOL, comprising: providing an IOL that includes an optic and a plate haptic; positioning an intraocular pressure sensor above an anterior side of the plate haptic; optionally positioning a soft gel above the IOL sensor;
positioning a multilayer conformal barrier coating above the soft gel; and optionally positioning a biocompatible coating above the barrier coating.
[0016] One aspect of the disclosure is a method of folding an IOL for delivery, comprising: providing an IOL that includes an optic and a plate haptic, and a pressure sensor disposed on the plate haptic; and folding the IOL along at least one fold line that is on a first side of the pressure sensor, the fold line not passing through an optical axis of the optic. [0017] One aspect of the disclosure is an intraocular lens, comprising: an optic and at least one plate haptic, and a pressure sensor embedded in the plate haptic.
[0018] One aspect of the disclosure is an intraocular lens, comprising: an optic and at least one plate haptic; and an antenna extending around a periphery of the IOL.
BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 illustrates an exemplary intraocular lens developed for implantation in canines.
[0020] Figure 2 illustrates an earlier exemplary IOL with an attached sensor.
[0021] Figures 3A and 3B illustrate an earlier exemplary IOL with an attached sensor.
[0022] Figure 4 illustrates an exemplary rigid PCB.
[0023] Figure 5 illustrates an exemplary flexible and transparent PCB.
[0024] Figure 6 illustrates details of an exemplary microstructure and layering of a multi-layer film.
[0025] Figures 7A, 7B and 7C illustrate an exemplary plate haptic IOL with an embedded intraocular pressure assembly.
[0026] Figure 8 illustrates an exemplary layering of components for any of the IOLs herein.
DETAILED DESCRIPTION
[0027] The present disclosure is related to the field of IOLs. In particular, the present disclosure relates to IOL wherein one or more sensors is attached (directly or indirectly) to at least one of the optic and the haptic(s) surface of the IOL, ensuring that the sensor does not significantly affect the optical performance or stability of the IOL in the eye. Preferably, the sensor is an intraocular pressure sensor.
[0028] In this disclosure, an intraocular sensor module means a capacitative or piezoresistive sensor that may comprise a separate package, or be on die (fabricated on the same silicon substrate as the rest of the electronic components). An intraocular pressure sensor assembly means the intraocular sensor and all the electronics that are may be used to operate the sensor, including, without limitation a microcontroller, voltage amplifiers, resistors and capacitors, memory units, RFID modules, batteries, and so on.
[0029] The intraocular pressure sensor can be mounted (directly or indirectly) on an intraocular lens, preferably designed for implantation in the posterior chamber. Attachment of an intraocular pressure sensor to the body an IOL has several advantages relative to commonly prescribed sites of fixation of such a sensor in intraocular space, for example, in the sclera (making it an intrascleral implant), in the subconjunctival space, the superchoroidal region, the vitreous, or in or near the Schlemms canal. An exemplary advantage of a sensor embedded in an IOL is that, by being embedded in the body of an IOL, the sensor is safely away from ocular tissue that may be otherwise disrupted by touch of the sensor body, for example, the iris or the corneal endothelium.
[0030] If the sensor is embedded on the anterior side of the IOL body and the IOL is placed in the capsular sac, the sensor is covered by the anterior capsule, and provided another layer of isolation and protected from cellular deposits and growth. At the same time, it is surrounded by flowing aqueous humor so that the pressure recorded by the sensor is the true intraocular pressure. Sensors embedded in the sclera, the vitreous or the subconjunctival space do not record pressure of the free flowing aqueous humor, but of ocular tissue in mechanical contact with the aqueous humor. The sensed pressure for those devices is therefore dampened by the modulus and the viscoelastic properties of the ocular tissue that surrounds the sensor.
[0031] Earlier examples of a design of an IOL with an attached sensor are shown and labeled in Figure 2 and 3. Figure 2 shows an exemplary intraocular lens 4 with an intraocular pressure sensor 10 mounted on its surface. Antenna 6 can be made of copper or a gold-titanium alloy, coated with gold, and is mounted around the periphery of the optic, as shown. The IOL also includes electronics 8 in communication with at least one of the antenna 6 and the pressure sensor 10. Pressure sensor 10 extends into the optical zone of the optic, and the antenna extends around the periphery of the optic portion. Figures 3A and 3B show an exemplary intraocular pressure sensor assembly 14 positioned on the anterior surface of an exemplary canine posterior chamber IOL 12. Antenna 16 is also shown extending around the periphery of the optic portion of the IOL. Again, the pressure sensor assembly 14 extends into a portion of the optic zone of the optic. Exemplary non-limiting dimensions include an optic diameter of 6 mm and overall length of the IOL of 14 mm.
[0032] Earlier examples of IOLs with embedded sensors and an electronic package that operates such sensors have the advantages of being compact and operationally functional because they maintain a clear central optic of 3 mm or larger in diameter. At the same time, some of these earlier designs do obscure part of the IOL optic, thereby compromising peripheral vision of dogs.
[0033] The current disclosure solves this problem by using a state of the art
microelectromechanical assembly that utilizes a flexible, transparent PCB. Transparent PCBs are a recent development, and the initial development led to rigid, transparent PCBs, as example of which is shown in Figure 4. The exemplary transparent PCB of figure 4 can be made of
Aluminum oxide (Alumina, 99.9%). Its properties, as published by the manufacturer (Elite Advanced Technologies, Penang, Malaysia) are listed below Exemplary advantages of transparent Alumina PCB include transparency up to 80-90%; high operating temperature up to 350°C; low expansion coefficient strong thermal properties (e.g., 26-28 W/mK); multi-layer circuits are possible; hermetic packages possible; and 0% water absorption. Other types of transparent PCBs have also been commercialized, utilizing polyimide, polyethylene
terephthalate, polycarbonate or glass as substrates.
[0034] None of these transparent substrates, however, meets the necessary requirements that the PCB material be flexible, transparent, biocompatible and function as an excellent barrier material, providing isolation from water, ions, and small and large proteins. These requirements are met by using Paralyne C or Grapahene as substrates. One example is a transparent PCB developed by COAT-X, located in La Chaux-de-Fonds, Switzerland. An example, as shown on their Website, is shown in Figure 5, which shows an example of a transparent, flexible PCB, developed by COAT-X. In one embodiment, the film is a multilayer structure 20 (see figure 6), comprised of a polymer film 24 with barrier properties such as Paralyne -C interspersed with layers of ceramic 22 such as SiOx. The ceramic material is the relatively thinner horizontal layers, and the polymeric material is represented as the relatively thicker horizontal layers. The film can be formed either as a free standing film, or a conformal coating to provide a hermetic seal around an implant or a portion of an implant, as disclosed in the following patents, incorporated by reference herein for all purposes, including methods of manufacture and methods of application to other materials - US Pat. No. 8,313,811; US Pat. No. 8,313,819; and US Pat. No. 8,361,591. Any and all methods of manufacturing and deposition described in these references are fully incorporated herein and can be used to manufacture any of the flexible components onto the IOLs herein. Additional details of the exemplary multilayer ceramic- polymer stack utilizing SiOx and Paralyne- C shown in figure 6 can be found in A. Hogg, et ah, “Protective multilayer packaging for long-term implantable medical devices”, in Surf. Coat. Technol. (2014), http://dx.doi.Org/10.1016/j.surfcoat.2014.02.070, which is incorporated by reference herein for all purposes.
[0035] Figure 6 shows details of exemplary microstructure and layering of these multi-layer films, illustrating permeation and diffusion by the arrows. The structure of the film can be used to alter or control the permeation and diffusion. Their effect on permeation and diffusion properties of these films have been discussed by Dr. Andreas Hogg in his Ph.D. thesis.
(Development and Characterization of Ultrathin Layer Packaging for Implantable Medical Devices), published in the website of COAT-X. ( http ;//coat-x .corn/), which is incorporated by reference herein for all purposes.
[0036] Figures 7A, 7B and 7C are top, side, and front views of an exemplary plate haptic IOL with an embedded intraocular pressure assembly. The IOL in figures 7A, 7B and 7C is a plate haptic IOL that is adapted to be foldable, and exemplary folding lines are shown as the two dashed lines.
[0037] Figs. 7A-7C illustrate exemplary IOL 40, which includes optic portion 42 and plate haptic portion 44. IOL also includes an intraocular pressure sensor assembly that includes sensor module 46 and electronics module 48, which are in electrical communication via electrical connectors 52. The IOL also includes antenna 50, which extends around the periphery of the IOL as shown, and is in electrical communication with connectors 52. Exemplary dimensions between the folding lines and sensor module 6 are .1 mm to .6 mm, such as .2mm to .45 mm, such as .35 mm.
[0038] As can be seen in the side views on figures 3B and 3C, sensor module 46 and electronics module 46 are embedded in the plate haptics of the IOL.
[0039] The multilayer barrier film has been utilized to populate the electronic module, for example, comprising a microcontroller, an intraocular pressure sensor, a memory, and an RFID module on the haptic of the plate haptic IOL. The location of the printed circuitry shown in figure 7 is an example and is not intended to be limiting. The antenna 50 and the conductive bus 52 may be disposed along the periphery of the IOL body, enabling the deployment of a substantially longer antenna loop, relative to the earlier designs shown in Figures 2 and 3.
[0040] The overall length of the loop antenna can be in the range of 20.0 mm - 30.0 mm, preferably in the range 22.0 mm to 26.0 mm. The antenna can be made of a wire of, for example, a diameter of 100 microns (such as in a range of 25-200 microns), and is preferably mounted on the anterior surface of the intraocular lens. Alternatively, the antenna can be comprised of a thin plate of gold or Nitinol coated with Gold, of thickness in the range of 10-50 microns and width in the range of 100 - 250 microns. The advantage of utilizing Nitinol in the antenna is that use of Nitinol improves the unfolding characteristics of the haptic subsequent to implantation through a small incision. The antenna and all other electrical elements may be bonded to the transparent multilayer film that is bonded to the surface of the intraocular lens, preferably the anterior surface. The antenna and the conductive bus may be directly deposited (e.g., via physical or chemical vapor deposition) on the transparent multilayer film. The overall thickness of the multilayer film can be about 10-100 microns (preferably, 20-75 microns).
[0041] Preliminary tests with a piezoresistive intraocular pressure sensor (received from Bosch) indicate that the sensor retains greater than 90% of its sensitivity when it is covered by a layer of a silicone (polysiloxane) polymer, then over-coated with the multilayer coating shown in Figure 6. Encapsulation of the sensor so that the sensor does not cause any adverse reaction in the eye is a challenge, since any encapsulation that provides excellent and durable barrier properties and is also endowed with a biocompatible surface may be expected to isolate the sensor from the hydrostatic and hydrodynamic pressure of the aqueous humor and therefore result in a loss of the sensitivity or response of the sensor, and may also introduce an undesirable time lag in the sensing process.
[0042] These problems have been solved by adding a layer of an inert soft gel, for example, a soft silicone gel, such as Silastic, available from Dow Corning, or Siluron, available from Geuder Corporation, Germany, then depositing the multilayer coating of figure 6 on top of the soft gel encapsulant. Preliminary tests indicate that this encapsulation package does not materially decrease sensor sensitivity. Tests clearly indicate that deposition of a material that has a bulk modulus exceeding 1 MPA adversely affects the response characteristics of the sensor. Therefore, the inventive designs herein meet this mechanical constraint while still providing the required biocompatibility and isolation of the sensor.
[0043] The implant comprising the IOL and the embedded intraocular pressure sensor, coated with the multilayer coating disclosed by Hogg is preferably coated with an organic
biocompatible coating that is designed to minimize adhesion of cortical and endothelial cells that are remnants of the crystalline lens that is removed prior to implantation of the IOL. Preferably, this coating minimizes stimulation of the inflammation cascade in the eye. The coating can be a multilayer amphiphilic or hydrophilic coating, with a gradation of cross-link density, glass transition temperature and bulk modulus. Its microstructure is that of a scaffold, with an inner layer with the highest cross-link density, and an outer layer of lowest cross-link density. The coating is applied via photopolymerization and comprises polyethylene glycol segments terminated with acrylate or methacrylate groups.
[0044] The plate haptic IOLs disclosed herein (e.g., in figures 7A and 7B) can be configured to engage the capsular equator at four points, and is therefore quite resistant to rotational displacement. It may not be vaulted, but a vault of up to 7 degrees is acceptable. A vault further separates the intraocular sensor assembly from the iris. The overall length of the IOL can be between 11.5 and 12.7 mm, preferably 12.5 mm. In exemplary figure 7A the exemplary length is shown as 12.3 mm. The IOL is preferably implanted in a folded state, preferably along lines bordering (on at least one side of) the electronic modules and the sensor module, such as is shown in figure 7 A. Such a folding pattern will enable the IOL to be delivered through a 3.3 mm incision. The haptic portions of the IOL can also be adapted to be more preferential to folding along the folding lines to facilitate folding in particular areas on both sides of the electronics modules and the sensor module.
[0045] One major advantage of the IOL designs herein over earlier designs is that it provides a full diameter optic, 6.0 mm in diameter. Alternative designs may be provided that have an optic of diameter from 5.0 mm to 6.5 mm, with an outer diameter of 6.0 to 7.5 mm. A second major advantage is that the IOLs herein allow an antenna of total length in the range of 20.0 to 25.0 mm, more than three time the length provided by previous designs.
[0046] The edge of the preferred plate haptic IOL is preferably designed to have a square profile. Since the edge of the optic has a thickness in the range of 50-150 microns, the overall thickness of the edge bearing the antenna coil will be in the range 150 - 525 microns, preferably 200-400 microns. This increase in edge thickness and a barrier on the anterior surface may eliminate migration of residual cortical and equatorial cells left over after phacoemulsification and cleaning of the capsular sac prior to lens implantation to the posterior capsule, and thus helps inhibit posterior capsular opacification (“PCO”).
[0047] Exemplary biocompatible coatings have been disclosed previously. Preferably it is made of a hydrogel material, and comprises two or more layers. The inner layers of this coating is preferably infused with pharmaceuticals, including an anticlotting agent, an antifibrotic agent, a corticosteroid and some other medicaments that downregulate expression of inflammation mediators such as cytokines. The multilayer coating, similar in molecular structure to an extracellular matrix prevents adhesion of giant cells, or polymorphic macrophage.
[0048] Figure 8 illustrates an exemplary layering of components for any of the IOLs herein. The sensor can be disposed above an anterior side of an IOL. An optional gel can be applied above the sensor or other sensor components. The multilayer barrier coating can then be positioned, which can be covered by an optional biocompatible coating.
[0049] As used herein, when this application refers to the optic being wholly or substantially free from obscuration, it generally refers to almost completely free of obscuration. There may be some obscuration in the most peripheral region of the optic. For example, in a top view, “substantially free” as used herein can mean that not less than 90% of the surface area is free of obscuration, or not less than 95%, or not less than 96%, or not less than 97%, or not less than 98%, or not less than 99%. For example, in figures 7A-7C, antenna 50 may extend slightly over the optic zone of the optic, but insignificantly.

Claims

1. An intraocular lens, comprising:
an optic and a plate haptic configured for four point fixation in the eye, optionally within a capsular sac; and
an embedded intraocular pressure (“IOP”) sensor assembly, wherein the intraocular pressure sensor assembly is mounted on a transparent substrate, wherein the substrate is attached to an anterior surface of the intraocular lens, and wherein the optic is wholly or substantially free from obscuration.
2. The IOL of claim 1, wherein said sensor assembly is mounted on the haptic of said IOL.
3. The IOL of claim 1 or 2, wherein the IOP sensor assembly is hermetically sealed.
4. The IOL of claim 1, 2 or 3, wherein the IOP sensor assembly comprises an
electronic module and a sensor module.
5. The IOL of any of claims 1-4 wherein the IOP sensor assembly comprises an IOP sensor that comprises a capacitative sensor.
6. The IOL of any of claims 1-4, wherein the IOP sensor assembly comprises an IOP sensor that comprises a piezoresistive sensor.
7. The IOL of any of claims 1-6, wherein the IOP sensor assembly comprises an IOP sensor that is covered with a soft gel, and wherein the soft gel is overcoated with a multilayer conformal barrier coating, and wherein the multilayer conformal barrier coating comprises at least one ceramic layer and at least one polymer layer.
8. The IOL of claim 7, wherein the multilayer conformal barrier coating has a
thickness in the range of 5-50 microns.
9. The IOL of any preceding claim, wherein the IOP sensor assembly comprises an IOP sensor, wherein the IOP sensor has dimensions in the range of 0.5 mm x 0.7 mm x 1.0 mm.
10. The IOL of claim 1, wherein the intraocular pressure (“IOP”) sensor assembly
comprises an antenna that is disposed around a periphery of the IOL, optionally in a curvilinear configuration around the periphery.
11. The IOL of claim 10, wherein the antenna comprises Titanium or Nitinol coated with Gold.
12. The IOL of claim 10, wherein the antenna has a length in the range of 20.0 mm to 30.0 mm.
13. The IOL of claim 10, wherein the antenna has a diameter of 25 microns to 100 microns.
14. The IOL of claim 10, wherein the antenna has a loop shape (e.g., annular) or at least a partial loop shape.
15. The IOL of claim 1, wherein the optic, the plate haptic, and the embedded
intraocular sensor assembly are coated with a multilayer conformal barrier coating comprising at least one ceramic layer and at least one polymer layer.
16. The IOL of claim 15, wherein the barrier coating is overcoated with a multilayer organic coating.
17. The IOL of claim 16, wherein the organic coating comprises an amphiphilic
polymer.
18. The IOL of claim 16, wherein the organic coating comprises polyethylene glycol segments.
19. The IOL of claim 15, wherein the barrier coating has a thickness in the range 5-50 microns.
20. The IOL of claim 1, wherein the plate haptics are configured for engaging a
capsular equator at four distinct locations.
21. The IOL of claim 1, wherein the IOL has an overall length in the range of 11.0 mm and 12.8 mm.
22. The IOL of claim 1, wherein the optic has a diameter in the range 5.0 mm to 6.5 mm.
23. A method of manufacturing an IOL, comprising:
providing an IOL that includes an optic and a plate haptic;
positioning an intraocular pressure sensor above an anterior side of the plate haptic; optionally positioning a soft gel above the IOL sensor;
positioning a multilayer conformal barrier coating above the soft gel; and optionally positioning a biocompatible coating above the barrier coating.
24. The method of claim 23, further comprising positioning an antenna around a
periphery of the IOL.
25. The method of claim 23, further comprising positioning an electronics module above the anterior side of IOL.
26. A method of folding an IOL for delivery, comprising:
providing an IOL that includes an optic and a plate haptic, and a pressure sensor disposed on the plate haptic; and
folding the IOL along at least one fold line that is on a first side of the pressure sensor, the fold line not passing through an optical axis of the optic.
27. An intraocular lens, comprising:
an optic and at least one plate haptic, and a pressure sensor embedded in the plate haptic.
28. The intraocular lens of claim 27, further comprising any of the features or
components described or claimed herein.
29. An intraocular lens, comprising:
an optic and at least one plate haptic; and
an antenna extending around a periphery of the IOL.
30. The intraocular lens of claim 29, further comprising any of the features or components described or claimed herein.
PCT/US2018/056277 2018-10-17 2018-10-17 Intraocular lenses with embedded intraocular pressure sensors WO2020081072A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/US2018/056277 WO2020081072A1 (en) 2018-10-17 2018-10-17 Intraocular lenses with embedded intraocular pressure sensors
US17/066,564 US20210137379A1 (en) 2018-10-17 2020-10-09 Intraocular lenses with embedded intraocular pressure sensors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2018/056277 WO2020081072A1 (en) 2018-10-17 2018-10-17 Intraocular lenses with embedded intraocular pressure sensors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/066,564 Continuation-In-Part US20210137379A1 (en) 2018-10-17 2020-10-09 Intraocular lenses with embedded intraocular pressure sensors

Publications (1)

Publication Number Publication Date
WO2020081072A1 true WO2020081072A1 (en) 2020-04-23

Family

ID=70284144

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/056277 WO2020081072A1 (en) 2018-10-17 2018-10-17 Intraocular lenses with embedded intraocular pressure sensors

Country Status (1)

Country Link
WO (1) WO2020081072A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11497399B2 (en) 2016-05-31 2022-11-15 Qura, Inc. Implantable intraocular pressure sensors and methods of use
US11517269B2 (en) 2018-05-07 2022-12-06 Qura, Inc. Providing monitoring services and access to information to caregivers, patients with implanted pressure sensors, and distributors
US11554009B2 (en) 2019-05-17 2023-01-17 Qura, Inc. Intraocular lenses with intraocular pressure sensors and methods of manufacture
US11602427B2 (en) 2018-03-30 2023-03-14 Qura, Inc. Intraocular lenses including an intraocular pressure sensor
US11684703B2 (en) 2018-02-20 2023-06-27 Qura, Inc. Coatings for implantable devices

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006067638A2 (en) * 2004-12-20 2006-06-29 Amo Groningen B.V. Amphiphilic block copolymers and their use
US20120238857A1 (en) * 2010-09-16 2012-09-20 Orthomems, Inc. Expandable implantable pressure sensor for intraocular surgery
US20130226293A1 (en) * 2012-02-23 2013-08-29 Novartis Ag Accommodative iol - refractive index change through change in polarizability of a medium
US8796942B2 (en) * 2011-05-24 2014-08-05 Samsung Electro-Mechanics Co., Ltd. LED circuit
US20160324628A1 (en) * 2014-01-08 2016-11-10 Elenza ,Inc. Electro-optical monofocal intraocular lens
US20170020660A1 (en) * 2015-07-23 2017-01-26 Elwha Llc Intraocular lens devices, systems, and related methods

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006067638A2 (en) * 2004-12-20 2006-06-29 Amo Groningen B.V. Amphiphilic block copolymers and their use
US20120238857A1 (en) * 2010-09-16 2012-09-20 Orthomems, Inc. Expandable implantable pressure sensor for intraocular surgery
US8796942B2 (en) * 2011-05-24 2014-08-05 Samsung Electro-Mechanics Co., Ltd. LED circuit
US20130226293A1 (en) * 2012-02-23 2013-08-29 Novartis Ag Accommodative iol - refractive index change through change in polarizability of a medium
US20160324628A1 (en) * 2014-01-08 2016-11-10 Elenza ,Inc. Electro-optical monofocal intraocular lens
US20170020660A1 (en) * 2015-07-23 2017-01-26 Elwha Llc Intraocular lens devices, systems, and related methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HOGG, A ET AL.: "Protective multilayer packaging for long-term implantable medical devices", SURFACE AND COATINGS TECHNOLOGY, vol. 255, 2014, pages 124 - 129, XP055704151, DOI: 10.1016/j.surfcoat.2014.02.070 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11497399B2 (en) 2016-05-31 2022-11-15 Qura, Inc. Implantable intraocular pressure sensors and methods of use
US11684703B2 (en) 2018-02-20 2023-06-27 Qura, Inc. Coatings for implantable devices
US11602427B2 (en) 2018-03-30 2023-03-14 Qura, Inc. Intraocular lenses including an intraocular pressure sensor
US11517269B2 (en) 2018-05-07 2022-12-06 Qura, Inc. Providing monitoring services and access to information to caregivers, patients with implanted pressure sensors, and distributors
US11554009B2 (en) 2019-05-17 2023-01-17 Qura, Inc. Intraocular lenses with intraocular pressure sensors and methods of manufacture

Similar Documents

Publication Publication Date Title
WO2020081072A1 (en) Intraocular lenses with embedded intraocular pressure sensors
US11602427B2 (en) Intraocular lenses including an intraocular pressure sensor
US11554009B2 (en) Intraocular lenses with intraocular pressure sensors and methods of manufacture
US20210137379A1 (en) Intraocular lenses with embedded intraocular pressure sensors
JP5785678B2 (en) Prosthetic lens capsule and method of inserting the same
US10729539B2 (en) Electro-chromic ophthalmic devices
US11684703B2 (en) Coatings for implantable devices
JP5065038B2 (en) Electric drive intraocular lens
US20130338767A1 (en) Devices and methods for dynamic focusing movement
US20060095128A1 (en) Electro-active intraocular lenses
US8900299B2 (en) Method in eye surgery
US20120238857A1 (en) Expandable implantable pressure sensor for intraocular surgery
US11806278B2 (en) Implantable intraocular drug delivery devices
US20210307609A1 (en) Implantable intraocular pressure sensors configured as capsular tension rings
Shim et al. Feasibility of intraocular projection for treatment of intractable corneal opacity
US20210353406A1 (en) Accommodative Functionality for Artificial Capsule Platform
EP3673321B1 (en) Electrowetting lenses having oleophobic surfaces
US20230120321A1 (en) Three-dimensional intraocular lens scaffold and add-in lens combination and methods of implantation
AU2012245172B2 (en) Electro-active intraocular lenses
US20230240834A1 (en) Pinhole Intraocular Onlay

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18936971

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18936971

Country of ref document: EP

Kind code of ref document: A1